Hearing on bonuses for top executives postponed
Judge seeks due diligence on employees eligible for payments
The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.
(Reuters) - The judge overseeing Purdue Pharmaâs Chapter 11 case has tentatively approved $16.1 million in retention payments for 506 of the company s employees but conditioned his ruling on the OxyContin makerâs successful reorganization.
During a virtual hearing, U.S. Bankruptcy Judge Robert Drain in White Plains, New York, said he would sign off on the payments â which he said are not the same as bonuses because they are part of the employeesâ annual compensation â as long as Purdue doesnât wind up liquidating in bankruptcy, which at this point in the case is a long shot.
Originally published on June 3, 2021 1:41 pm
After more than a year of high-stakes negotiations with billions of dollars on the line, a bankruptcy plan for Purdue Pharma, the maker of OxyContin, cleared a major hurdle late Wednesday.
Federal Judge Robert Drain in White Plains, N.Y., moved the controversial deal forward despite objections from dozens of state attorneys general, setting the stage for a final vote by the company s creditors expected this summer.
The drugmaker filed for Chapter 11 protection in 2019 facing an avalanche of lawsuits tied to its aggressive opioid sales practices.
Public health experts and many government officials say the introduction of OxyContin fueled the nation s deadly opioid epidemic.
KUOW - Sackler Family Empire Poised To Win Immunity From Opioid Lawsuits kuow.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kuow.org Daily Mail and Mail on Sunday newspapers.
A federal bankruptcy judge cleared a plan for final vote by Purdue Pharma s creditors that would release members of the Sackler family and their financial empire from liability for the opioid crisis.